Skip to main content
. 2020 May 31;13(6):1251–1259. doi: 10.1111/cts.12812

Figure 2.

Figure 2

Effect of EVR on T cell proliferation. CD4+ and CD8+ T cell proliferation in peripheral blood mononuclear cells (PBMCs) that were isolated before (day (D)1) and after (D3, D8, and D15) oral administration of EVR in participants of the low‐dose (1.5 mg), medium‐dose (2.25 mg), and high‐dose (3 mg) groups and treated with anti‐CD3 and anti‐CD28 (both 50 ng/mL) for 48 hours (a). CD4+ and CD8 + T cell proliferation in drug‐naive PBMCs isolated on D1 and stimulated with anti‐CD3 (50 ng/mL) in the presence (+) and absence (‐) of EVR (10 nM) for 48 hours (b). Data are represented as mean ± SD. Differences were analyzed by Wilcoxon test. */#/§ P < 0.05 vs. D1 a, **P < 0.01, ***P < 0.001 vs. unstimulated cells, ### P < 0.001 vs. treated cells b. EVR, everolimus.